Treating low calcium levels in the blood of patients undergoing chronic kidney dialysis. It may also be used for other conditions as determined by your doctor.
Calcijex solution is a form of vitamin D. It works by promoting proper absorption and use of calcium and phosphate by the body in normal bone development and maintenance.
Submit your review
All medicines may cause side effects, but many people have no, or minor, side effects. When used in small doses, no COMMON side effects have been reported with this product. Seek medical attention right away if any of these SEVERE side effects occur:
Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); bizarre behavior; bone pain; constipation; decreased sex drive; diarrhea; difficult or painful urination; dizziness; drowsiness; dry mouth; eye redness or irritation; fever; flushing; frequent urination; headache; increased body temperature; increased thirst; irregular heartbeat; loss of appetite; mental or mood changes; metallic taste; muscle pain; nausea; runny nose; sensitivity of the eyes to sunlight; stomach pain or cramps; unexplained weight loss; unusual thinking; vomiting; weakness.
The recommended initial dose of Calcijex, depending on the severity of the hypocalcemia and/or secondary hyperparathyroidism, is 1 mcg (0.02 mcg/kg) to 2 mcg administered intravenously three times weekly, approximately every other day. Doses as small as 0.5 mcg and as large as 4 mcg three times weekly have been used as an initial dose. If a satisfactory response is not observed, the dose may be increased by 0.5 to 1 mcg at two to four week intervals. During this titration period, serum calcium and phosphorus levels should be obtained at least twice weekly. If hypercalcemia or a serum calcium times phosphate product greater than 70 is noted, the drug should be immediately discontinued until these parameters are appropriate. Then, the Calcijex dose should be reinitiated at a lower dose. Doses may need to be reduced as the PTH levels decrease in response to the therapy.